The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

Research Report
  ()
The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.

Life Sciences Co. Exceeds Expectations in Q3/22

Research Report
  ()
During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.

Pharma Co. Won't See Bump in Sales From New COVID Drug

Research Report
  ()
The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

  ()
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

  ()
With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.

Nine Stocks Expert Says Should Pique Your Interest

Contributed Opinion
  ()
Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on.

Clean Nuclear Med Tech With Quantum Blue Sky

Contributed Opinion
  ()
With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current

Research Report
  ()
This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report.

Potential ROI With German Biopharma Co. Notable

Research Report
  ()
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'

Contributed Opinion
  ()
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy it.

Showing Results: 1 to 25 of 147 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts